News ReleasesPrinter friendly version
Protox Therapeutics Announces Presentation of Data at Leading Cancer Research Conference
Monday, April 3, 2006 - Vancouver, Canada - Protox Therapeutics Inc. (TSX-V: PRX) announced
today that preclinical data demonstrating PRX302’s validity as a treatment for prostate
cancer and benign prostatic hyperplasia (BPH) is being presented in a poster session at
the 97th Meeting of the American Association of Cancer Research (AACR), which is being
held this week at the Washington Convention Centre in Washington, D.C.
The poster, entitled PSA-Activated Proaerolysin as a Prostate Specific Cancer Therapy,
summarizes data generated from studies conducted at the Cancer Research Institute at
Scott & White Hospital in Temple, Texas under the direction of Dr. Arthur Frankel. The
results confirm that PRX302, Protox’s lead drug, is preferentially activated by PSA
(prostate specific antigen) and selectively kills PSA producing cells. This selectivity
is expected to translate into an effective treatment with less toxicity than current
treatments for both prostate cancer and BPH, conditions in which PSA is produced in elevated
levels by prostate cells.
The presentation will take place on April 3rd, 2006 between 8:00a.m. and 12:00p.m. EST in
the Exhibit Hall, Poster Section 17, number 19. Earlier this year, Protox received FDA
clearance to begin a Phase I clinical trial with PRX302 for the treatment of localized
prostate cancer. The trial is expected to begin in the second quarter of 2006.
About The AACR Annual Meeting:
The AACR Annual Meeting is the world's largest and most comprehensive gathering of
professionals in the cancer field, encompassing basic, translational, and clinical
research. This prestigious annual conference highlights the latest developments in cancer
research and is attended by over 25,000 delegates from universities, research institutions
and the pharmaceutical industry.
About Protox Therapeutics:
Protox Therapeutics is a product-focused development-stage company and a leader in
advancing novel, targeted protein toxin therapeutics for treatment of cancer and
other diseases. Through the company’s PORxin™ technology platform,
therapeutic candidates are generated by engineering the naturally occurring protein,
pro-aerolysin. These proteins become potent anti-cancer agents when activated at a
tumor site by specific proteases produced by cancer cells. Once activated, the drug
punches holes in the cancer cells causing the contents to leak out and ultimately,
cell death. Protox has received clearance from the FDA to commence Phase 1 clinical
trials with the lead compound, PRX302, for the treatment of localized prostate cancer.
PRX302 is also being developed for treatment of benign prostatic hyperplasia.
For more information, contact:
Elayne Wandler
Director, Investor Relations and Corporate Communications, Protox Therapeutics Inc.
Direct: 604-688-4369
Cell: 778-865-0172
Fax: 604-688-0173
ewandler@protoxtherapeutics.com
|
